237 related articles for article (PubMed ID: 35278676)
1. PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer.
Wu Y; Wang Z; Han L; Guo Z; Yan B; Guo L; Zhao H; Wei M; Hou N; Ye J; Wang Z; Shi C; Liu S; Chen C; Chen S; Wang T; Yi J; Zhou J; Yao L; Zhou W; Ling R; Zhang J
Mol Ther; 2022 Jul; 30(7):2603-2617. PubMed ID: 35278676
[TBL] [Abstract][Full Text] [Related]
2. Novel Chemicals Derived from Tadalafil Exhibit PRMT5 Inhibition and Promising Activities against Breast Cancer.
Yang Z; Xiao T; Li Z; Zhang J; Chen S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563196
[TBL] [Abstract][Full Text] [Related]
3. ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer.
Liu H; Lyu H; Jiang G; Chen D; Ruan S; Liu S; Zhou L; Yang M; Zeng S; He Z; Wang H; Li H; Zheng G; Liu B
Cancer Res; 2022 Nov; 82(21):3974-3986. PubMed ID: 36069931
[TBL] [Abstract][Full Text] [Related]
4. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
Wang Z; Kong J; Wu Y; Zhang J; Wang T; Li N; Fan J; Wang H; Zhang J; Ling R
Breast Cancer Res Treat; 2018 Apr; 168(2):531-542. PubMed ID: 29185119
[TBL] [Abstract][Full Text] [Related]
5. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.
Yu F; Wei J; Cui X; Yu C; Ni W; Bungert J; Wu L; He C; Qian Z
Nucleic Acids Res; 2021 Jun; 49(10):5779-5797. PubMed ID: 34048572
[TBL] [Abstract][Full Text] [Related]
6. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
7. Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer.
Zhang D; Ning J; Okon I; Zheng X; Satyanarayana G; Song P; Xu S; Zou MH
Cell Death Dis; 2021 May; 12(6):518. PubMed ID: 34016959
[TBL] [Abstract][Full Text] [Related]
8. RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway.
Jiang Y; Wan Y; Gong M; Zhou S; Qiu J; Cheng W
J Cell Mol Med; 2020 Jun; 24(11):6137-6148. PubMed ID: 32329191
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells.
Zhang C; Zhi WI; Lu H; Samanta D; Chen I; Gabrielson E; Semenza GL
Oncotarget; 2016 Oct; 7(40):64527-64542. PubMed ID: 27590511
[TBL] [Abstract][Full Text] [Related]
10. m6A readers, writers, erasers, and the m6A epitranscriptome in breast cancer.
Petri BJ; Klinge CM
J Mol Endocrinol; 2023 Feb; 70(2):. PubMed ID: 36367225
[TBL] [Abstract][Full Text] [Related]
11. m6A methylation regulates hypoxia-induced pancreatic cancer glycolytic metabolism through ALKBH5-HDAC4-HIF1α positive feedback loop.
Liu X; Feng M; Hao X; Gao Z; Wu Z; Wang Y; Du L; Wang C
Oncogene; 2023 Jun; 42(25):2047-2060. PubMed ID: 37149664
[TBL] [Abstract][Full Text] [Related]
12. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
13. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Chen H; Lorton B; Gupta V; Shechter D
Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
[TBL] [Abstract][Full Text] [Related]
14. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
15. Distinct RNA
Toh JDW; Crossley SWM; Bruemmer KJ; Ge EJ; He D; Iovan DA; Chang CJ
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25284-25292. PubMed ID: 32989163
[TBL] [Abstract][Full Text] [Related]
16. ALKBH5 facilitates CYP1B1 mRNA degradation via m6A demethylation to alleviate MSC senescence and osteoarthritis progression.
Ye G; Li J; Yu W; Xie Z; Zheng G; Liu W; Wang S; Cao Q; Lin J; Su Z; Li D; Che Y; Fan S; Wang P; Wu Y; Shen H
Exp Mol Med; 2023 Aug; 55(8):1743-1756. PubMed ID: 37524872
[TBL] [Abstract][Full Text] [Related]
17. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of m6A-factors METTL3, ALKBH5, and YTHDC1 alters HPV16 mRNA splicing.
Cui X; Nilsson K; Kajitani N; Schwartz S
Virus Genes; 2022 Apr; 58(2):98-112. PubMed ID: 35190939
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-induced m6A demethylase ALKBH5 promotes ovarian cancer tumorigenicity by decreasing methylation of the lncRNA RMRP.
Lyu Y; Wang Y; Ding H; Li P
Am J Cancer Res; 2023; 13(9):4179-4191. PubMed ID: 37818080
[TBL] [Abstract][Full Text] [Related]
20. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
Nie S; Zhang L; Liu J; Wan Y; Jiang Y; Yang J; Sun R; Ma X; Sun G; Meng H; Xu M; Cheng W
J Exp Clin Cancer Res; 2021 Sep; 40(1):284. PubMed ID: 34496932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
